Sanofi's Nuvaxovid Shows Superior Tolerability Over Moderna's MNEXSPIKE In COMPARE Study

Sanofi's protein-based COVID-19 vaccine Nuvaxovid (NVX-CoV2705) showed a significantly better tolerability profile than Moderna's mNEXSPIKE in the first head-to-head, double-blind, randomized phase 4 study. The result is a modest positive for Sanofi’s vaccine positioning and supports its product differentiation versus mRNA competitors. Market impact is likely limited to the individual names rather than the broader sector.

Analysis

Sanofi's protein-based COVID-19 vaccine Nuvaxovid (NVX-CoV2705) showed a significantly better tolerability profile than Moderna's mNEXSPIKE in the first head-to-head, double-blind, randomized phase 4 study. The result is a modest positive for Sanofi’s vaccine positioning and supports its product differentiation versus mRNA competitors. Market impact is likely limited to the individual names rather than the broader sector.